| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Forest Labs., LLC v. Apotex Corp., 15- 0018 (D. Del.) |
Jan. 5, 2015 | Hon. Gregory M. Sleet | Teflaro® (ceftaroline fosamil injection for intravenous) |
6,417,175
6,906,055
7,419,973
8,247,400
|
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00522 (PTAB) | Jan. 5, 2015 | N/A | INOmax® (nitric oxide) | 8,282,966 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00524 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,293,284 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00525 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,431,163 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00526 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,795,741 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00529 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,846,112 |
| Iceutica Pty Ltd. v. Lupin Ltd., 15-0045 (D. Md.) | Jan. 7, 2015 | Hon. J. Frederick Motz | Zorvolex® (diclofenac capsules) | 8,679,544 |
| Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., 15-0018 (M.D.N.C.) | Jan. 7, 2015 | Hon. N. C. Tilley, Jr. | Jevtana® Kit (cabazitaxel injection) | 5,847,170 |
| Pfizer Inc. v. Mylan Inc., 15-0026 (D. Del.) | Jan. 8, 2015 | Hon. Sue L. Robinson | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
|
| Salix Pharms., Inc. v. Novel Labs., Inc., 15-0027 (D. Del.) | Jan. 8, 2015 | Hon. Gregory M. Sleet | Apriso® (mesalamine capsules) | 8,865,688 |
| Otsuka Pharm. Co., Ltd. v. Hetero Drugs Ltd., 15-0161 (D.N.J.) | Jan. 8, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,580,796
8,642,760
8,759,350
|
| Jazz Pharms., Inc. v. Par Pharm, Inc., 15-0173 (D.N.J.) | Jan. 8, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,859,619 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00545 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,589,182 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00546 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,765,106 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00547 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,765,107 |
| Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2015-00548 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,895,059 |
| Teva Pharms. USA, Inc. v. ViiV Healthcare Co., IPR2015-00550 (PTAB) | Jan. 8, 2015 | N/A | Trizivir® (abacavir sulfate / lamivudine / zidovudine) | 6,417,191 |
| Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2015-00551 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,457,988 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00554 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,668,730 |
| Jazz Pharms., Inc. v. Ranbaxy Labs. Ltd., 15-0187 (D.N.J.) | Jan. 9, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,859,619 |
| Pfizer Inc. v. Mylan Inc., 15-0004 (N.D.W.V.) | Jan. 9, 2015 | Hon. Irene M. Keeley | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
|
| Horizon Pharma Ireland Ltd. v. Paddock Labs., LLC, 15-0368 (D.N.J.) | Jan. 13, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Johnson Matthey Inc. v. Pfizer, Inc., 15-0014 (E.D. Va.) | Jan. 13, 2015 | Hon. Arenda L. Wright Allen | Tikosyn® (dofetilide capsules) | 6,124,363 |
| Actelion Pharms Ltd. v. Icos Corp., IPR2015-00561 (PTAB) | Jan. 13, 2015 | N/A | Cialis® (tadalafil tablets) | 7,182,958 |
| Actelion Pharms Ltd. v. Icos Corp., IPR2015-00562 (PTAB) | Jan. 13, 2015 | N/A | Cialis® (tadalafil tablets) | 6,821,975 |
| Millennium Pharms., Inc. v. Hetero Labs Ltd., 15-0039 (D. Del.) | Jan. 14, 2015 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Millennium Pharms., Inc. v. Onco Therapies Ltd., 15-0040 (D. Del.) | Jan. 14, 2015 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Horizon Pharma Ireland Ltd. v. Paddock Labs., LLC, 15-0043 (D. Del.) | Jan. 14, 2015 | Hon. Sue L. Robinson | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharms. Ltd., 15-0280 (D.N.J.) | Jan. 14, 2015 | Hon. Stanley R. Chesler | Latuda® (lurasidone hydrochloride tablets) | 5,532,372 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Invagen Pharms., Inc., 15-0281 (D.N.J.) | Jan. 14, 2015 | Hon. Stanley R. Chesler | Latuda® (lurasidone hydrochloride tablets) | 5,532,372 |
| Alcon Labs., Inc. v. Akorn, Inc., 15-0285 (D.N.J.) | Jan. 14, 2015 | Hon. Madeline C. Arleo | Durezol® (difluprednate ophthalmic emulsion) | 6,114,319 |
| Sanofi-Aventis U.S. LLC v. Apotex Corp., 15-0287 (D.N.J.) | Jan. 14, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 15-0289 (D.N.J.) | Jan. 14, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Onco Therapies Ltd., 15-0290 (D.N.J.) | Jan. 14, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Apotex Corp., 15-0044 (D. Del.) | Jan. 15, 2015 | Hon. Leonard P. Stark | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 15-80056 (S.D. Fla.) | Jan. 15, 2015 | Hon. Donald M. Middlebrooks | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Laboratoire HRA Pharma v. Teva Pharms. USA, Inc., 15-0045 (D. Del.) | Jan. 16, 2015 | Hon. Richard G. Andrews | Ella® (ulipristal acetate oral tablets) |
8,426,392
8,512,745
8,735,380
|
| Boehringer Ingelheim GmbH & Co. KG v. Teva Pharms. USA, Inc., 15-0048 (D. Del.) | Jan. 16, 2015 | Hon. Sue L. Robinson | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Shionogi & Co., Ltd. v. Aurobindo Pharma Ltd., 15-0319 (D.N.J.) | Jan. 16, 2015 | Hon. Michael A. Shipp | Doribax® (doripenem for injection) | 8,247,402 |
| Supernus Pharms., Inc. v. Par Pharm. Cos., Inc., 15-0326 (D.N.J.) | Jan. 16, 2015 | Hon. Susan D. Wigenton | Trokendi XR® (topiramate extended-release capsules) |
8,298,576
8,298,580
8,663,683
8,877,248
|
| Senju Pharm. Co., Ltd. v. Lupin, Ltd., 15-0335 (D.N.J.) | Jan. 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,871,813
8,927,606
|
| Senju Pharm. Co., Ltd. v. Apotex Inc., 15-0336 (D.N.J.) | Jan. 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| Senju Pharm. Co., Ltd. v. Paddock Labs., LLC, 15-0337 (D.N.J.) | Jan. 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| Supernus Pharms., Inc. v. TWi Pharms., Inc., 15-0369 (D.N.J.) | Jan. 16, 2015 | Hon. Renee Marie Bumb | Oxtellar XR® (oxcarbazepine extended-release tablets) |
7,722,898
7,910,131
8,617,600
8,821,930
|
| Shionogi & Co., Ltd. v. Aurobindo Pharma Ltd., 15-0478 (N.D. Ill.) | Jan. 16, 2015 | Hon. Robert W. Gettleman | Doribax® (doripenem for injection) | 8,247,402 |
| Teva Pharms. USA, Inc. v. AstraZeneca Pharms. LP, 15-0050 (D. Del.) | Jan. 19, 2015 | Hon. Gregory M. Sleet | Byetta® (exenatide injection) |
7,297,761
7,741,269
|
| Tris Pharma Inc. v. Par Pharm., Inc., 15-0068 (D. Del.) | Jan. 21, 2015 | Hon. Gregory M. Sleet |
Quillivant XR® (methylphenidate hydrochloride
extended-release oral suspension)
|
8,062,667
8,287,903
8,465,765
8,563,033
8,778,390
|
| Boehringer Ingelheim GmbH & Co. KG v. Mylan Pharms. Inc., 15-0010 (N.D.W.V.) | Jan. 21, 2015 | Hon. Irene M. Keeley | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Teva Pharms. USA, Inc. v. Dr. Reddy’s Labs., Ltd., 15-0471 (D.N.J.) | Jan. 22, 2015 | Hon. Claire C. Cecchi | Copaxone® (glatiramer acetate for injection) | 5,800,808 |
| Teva Pharms. USA, Inc. v. Synthon Pharms., Inc., 15-0472 (D.N.J.) | Jan. 22, 2015 | Hon. Claire C. Cecchi | Copaxone® (glatiramer acetate for injection) | 5,800,808 |
| Acorda Therapeutics, Inc. v. Actavis Labs. FL, Inc., 15-0077 (D. Del.) | Jan. 23, 2015 | Hon. Leonard P. Stark | Ampyra® (dalfampridine extended-release tablets) | 5,540,938 |
| Novartis Pharms. Corp. v. Par Pharm., Inc., 15-0078 (D. Del.) | Jan. 23, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772
7,297,703
7,741,338
|
| Pfizer Inc. v. Mylan Pharms. Inc., 15-0079 (D. Del.) | Jan. 23, 2015 | Hon. Gregory M. Sleet | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| Astellas Pharma Inc. v. Fresenius Kabi USA, LLC, 15-0080 (D. Del.) | Jan. 23, 2015 | Hon. Leonard P. Stark | Mycamine® (micafungin sodium for injection) |
6,107,458
6,774,104
|
| Eli Lilly and Co. v. Fresenius Kabi USA, LLC, 15-0096 (S.D. Ind.) | Jan. 23, 2015 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed disodium for intravenous infusion) | 7,772,209 |
| Spectrum Pharms., Inc. v. Amneal Pharms. LLC, 15-0139 (D. Nev.) | Jan. 23, 2015 | Hon. James C. Mahan | Fusilev® (levoleucovorin calcium for injection) | 6,500,829 |
| Senju Pharm. Co., Ltd. v. Paddock Labs., LLC, 15-0087 (D. Del.) | Jan. 26, 2015 | Hon. Sue L. Robinson | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| AstraZeneca Pharms. LP v. Glenmark Pharms. Ltd., 15-0615 (D.N.J.) | Jan. 26, 2015 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Pfizer Inc. v. Mylan Pharms. Inc., 15-0013 (N.D.W.V.) | Jan. 27, 2015 | Hon. Irene M. Keeley | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| Otsuka Pharm. Co., Ltd. v. Apotex Inc., 15-0109 (D. Del.) | Jan. 29, 2015 | Hon. Richard G. Andrews | Samsca® (tolvaptan tablets) |
5,753,677
8,501,730
|
| Bayer Healthcare LLC v. Mylan Pharms. Inc., 15-0114 (D. Del.) | Jan. 30, 2015 | Hon. Leonard P. Stark | Nexavar® (sorafenib tosylate tablets) |
8,618,141
8,877,933
|
| Shionogi & Co., Ltd. v. Apotex Corp., 15-0668 (D.N.J.) | Jan. 30, 2015 | Hon. Peter G. Sheridan | Doribax® (doripenem for injection) | 8,247,402 |
| Celgene Corp. v. Lannett Holdings, Inc., 15-0697 (D.N.J.) | Jan. 30, 2015 | Hon. Susan D. Wigenton | Thalomid® (thalidomide capsules) |
6,045,501
6,315,720
6,561,976
6,561,977
6,755,784
6,869,399
7,141,018
7,230,012
7,435,745
7,874,984
7,959,566
8,204,763
8,315,886
8,589,188
8,626,531
|
| Cosmo Technologies Ltd. v. Par Pharm., Inc., 15-0116 (D. Del.) | Feb. 2, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
7,431,943
8,293,273
8,784,888
8,895,064
RE43,799
|
| Cephalon, Inc. v. Unimark Remedies Ltd., 15-0117 (D. Del.) | Feb. 2, 2015 | Hon. Gregory M. Sleet | Nuvigil® (armodafinil tablets) | 7,132,570 |
| Sanofi-Aventis U.S. LLC v. Actavis LLC, 15-0776 (D.N.J.) | Feb. 2, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Teva Pharms. USA, Inc. v. Amneal Pharms. LLC, 15-0124 (D. Del.) | Feb. 3, 2015 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate for injection) |
8,232,250
8,399,413
|
| Mylan Pharms. Inc. v. Warner-Chilcott Co. LLC, IPR2015-00682 (PTAB) | Feb. 3, 2015 | N/A |
Lo Loestrin® Fe
(ethinyl estradiol / norethindrone acetate tablets)
|
7,704,984 |
| Orexo AB v. Actavis Labs. FL, Inc., 15-0826 (D.N.J.) | Feb. 4, 2015 | Hon. Peter G. Sheridan | Abstral® (fentanyl sublingual tablets) |
6,759,059
6,761,910
7,910,132
|
| AstraZeneca AB v. Perrigo Co. PLC, 15-1057 (D.N.J.) | Feb. 4, 2015 | Hon. Mary L. Cooper |
Nexium 24HR®
(esomeprazole magnesium delayed-release capsules)
|
6,369,085
7,411,070
|
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-0128 (D. Del.) | Feb. 5, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772
7,297,703
7,741,338
|
| Novartis Pharms. Corp. v. BPI Labs LLC, 15-0950 (D.N.J.) | Feb. 5, 2015 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid for injection) | 8,324,189 |
| Jazz Pharms., Inc. v. Amneal Pharms., LLC, 15-1043 (D.N.J.) | Feb. 6, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
8,731,963
8,772,306
8,859,619
|
| Dr. Reddy’s Labs., Inc. v. Fresenius Kabi USA, LLC, IPR2015-00715 (PTAB) | Feb. 6, 2015 | N/A | Diprivan® (propofol injectable) | 8,476,010 |
| Mylan Pharms. Inc. v. Yeda Research & Development Co. Ltd., IPR2015-00644 (PTAB) | Feb. 7, 2015 | N/A | Copaxone® (glatiramer acetate for injection) | 8,399,413 |
| Novartis Pharms. Corp. v. BPI Labs, LLC, 15-0272 (M.D. Fla.) | Feb. 9, 2015 | Hon. Susan C Bucklew | Zometa® (zoledronic acid for injection) | 8,324,189 |
| Roxane Labs., Inc. v. Lupin Ltd., 15-1095 (D.N.J.) | Feb. 10, 2015 | Hon. Stanley R. Chesler | PhosLo® GelCaps (calcium acetate capsules) | 8,563,032 |
| Novartis AG v. Ezra Ventures, LLC, 15-0150 (D. Del.) | Feb. 11, 2015 | Hon. Leonard P. Stark | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Novartis AG v. HEC Pharm Co., Ltd., 15-0151 (D. Del.) | Feb. 11, 2015 | Hon. Leonard P. Stark | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Novo Nordisk Inc. v. Sun Pharm. Indus. Ltd., 15-1287 (D.N.J.) | Feb. 12, 2015 | Hon. Michael A. Shipp | Vagifem® (estradiol tablets) | 7,018,992 |
| Forest Labs., LLC v. Alembic Pharms. Ltd., 15-0158 (D. Del.) | Feb. 13, 2015 | Hon. Sue L. Robinson | Saphris® (asenapine maleate tablets) | 5,763,476 |
| AbbVie, Inc. v. Mylan Pharms. Inc., 15-1402 (N.D. Ill.) | Feb. 13, 2015 | Hon. Robert W. Gettleman | Kaletra® (lopinavir / ritonavir tablets) |
8,025,899
8,268,349
8,309,613
8,377,952
8,399,015
8,470,347
8,691,878
|
| Helsinn Healthcare S.A. v. Gavis Pharma LLC, 15-1228 (D.N.J.) | Feb. 13, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Novartis AG v. Ezra Ventures, LLC, 15-0095 (E.D. Ark.) | Feb. 13, 2015 | Hon. Kristine G. Baker | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 15-0164 (D. Del.) | Feb. 17, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
7,431,943
8,293,273
8,784,888
8,895,064
RE43,799
|
| INO Therapeutics LLC v. Praxair Distribution, Inc., 15-170 (D. Del.) | Feb. 19, 2015 | Hon. Gregory M. Sleet | INOmax® (nitric oxide for inhalation) |
8,282,966
8,293,284
8,431,163
8,795,741
8,846,112
8,291,904
8,573,210
8,573,209
8,776,794
8,776,795
|
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 15-1312 (D.N.J.) | Feb. 19, 2015 | Hon. Madeline C. Arleo | Uceris® (budesonide tablets) |
7,410,651
7,431,943
8,293,273
8,784,888
8,895,064
RE43,799
|
| Ferring Pharms. Inc. v. Par Pharm., Inc., 15-0173 (D. Del.) | Feb. 20, 2015 | Hon. Richard G. Andrews |
Prepopik®
(sodium picosulfate / magnesium oxide / citric acid solution)
|
8,450,338
8,481,083
|
| Fresenius Medical Care Holdings, Inc. v. Novel Labs., Inc., 15-10472 (D. Mass.) | Feb. 20, 2015 | Hon. Richard G. Stearns | PhosLo® GelCaps (calcium acetate) |
6,576,665
6,875,445
|
| Jazz Pharms., Inc. v. Roxane Labs., Inc., 15-1360 (D.N.J.) | Feb. 20, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
8,461,203
8,772,306
8,859,619
|
| Fresenius Medical Care Holdings, Inc. v. Novel Labs., Inc., 15-1361 (D.N.J.) | Feb. 20, 2015 | Hon. Peter G. Sheridan | PhosLo® GelCaps (calcium acetate) |
6,576,665
6,875,445
|
| Cephalon, Inc. v. Sandoz Inc., 15-0178 (D. Del.) | Feb. 23, 2015 | Hon. Gregory M. Sleet | Treanda® (bendamustine hydrochloride for infusion) |
8,669,279
8,883,836
8,895,756
|
| Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., 15-0179 (D. Del.) | Feb. 23, 2015 | Hon. Gregory M. Sleet | Treanda® (bendamustine hydrochloride for infusion) |
8,669,279
8,883,836
8,895,756
|
| Shire LLC v. Par Pharm., Inc., 15-1454 (D.N.J.) | Feb. 26, 2015 | Hon. Renee Marie Bumb |
Adderall XR® (dextroamphetamine sulfate /
dextroamphetamine saccharate /
amphetamine aspartate monohydrate /
amphetamine sulfate tablets)
|
RE42,096
RE41,148
|
| Purdue Pharma L.P. v. Actavis Labs. UT, Inc., 15-0192 (D. Del.) | Feb. 27, 2015 | Hon. Sue L. Robinson | Butrans® (buprenorphine transdermal system) |
RE41,408
RE41,489
RE41,571
|
| Cosmo Technologies Ltd. v. Alvogen Pine Brook, Inc., 15-0193 (D. Del.) | Feb. 27, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
8,784,888
RE43,799
|
| AstraZeneca Pharms. LP v. Macleods Pharms., Ltd., 15-1513 (D.N.J.) | Feb. 27, 2015 | Hon. Claire C. Cecchi |
Seroquel XR®
(quetiapine fumarate extended-release tablets)
|
5,948,437 |
| Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-00817 (PTAB) | Feb. 27, 2015 | N/A | Ampyra® (dalfampridine extended-release tablets) | 8,007,826 |
| Otsuka Pharm. Co., Ltd. v. Amneal Pharms. LLC, 15-1585 (D.N.J.) | Mar. 2, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Mylan Pharms. Inc. v. Yeda Research & Development Co. Ltd., IPR2015-00830 (PTAB) | Mar. 3, 2015 | N/A |
Copaxone®
(glatiramer acetate for injection)
|
8,969,302 |
| Vivus, Inc. v. Actavis Labs. FL, Inc., 15-1636 (D.N.J.) | Mar. 4, 2015 | Hon. Stanley R. Chesler |
Qsymia® (phentermine /
topiramate extended-release capsules)
|
8,895,057
8,895,058
|
| Novartis AG v. HEC Pharm Co., Ltd., 15-1647 (D.N.J.) | Mar. 5, 2015 | Hon. Claire C. Cecchi | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Boehringer Ingelheim Pharma GMBH & Co. KG v. Breckenridge Pharm., Inc., 15-1662 (D.N.J.) | Mar. 5, 2015 | Hon. Mary L. Cooper | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Baxter Healthcare Corp. v. Sagent Pharms. Inc., 15-1684 (D.N.J.) | Mar. 6, 2015 | Hon. Jerome B. Simandle |
Brevibloc®
(esmolol hydrochloride in sodium chloride solution)
|
6,310,094
6,528,540
|
| Otsuka Pharm. Co., Ltd. v. Wockhardt Bio AG, 15-1690 (D.N.J.) | Mar. 6, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,759,350
7,053,092
|
| Biomarin Pharm. Inc. v. Par Pharm., Inc., 15-1706 (D.N.J.) | Mar. 6, 2015 | Hon. Michael A. Shipp | Kuvan® (sapropterin dihydrochloride tablets) |
7,566,462
7,566,714
7,612,073
7,727,987
8,003,126
8,067,416
RE43,797
8,318,745
|
| Baxter Healthcare Corp. v. Sagent Pharms. Inc., 15-2076 (N.D. Ill.) | Mar. 9, 2015 | Hon. Richard A. Posner |
Brevibloc®
(esmolol hydrochloride in sodium chloride solution)
|
6,310,094
6,528,540
|
| Otsuka Pharm. Co., Ltd. v. Sandoz Inc., 15-1716 (D.N.J.) | Mar. 9, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Allergan Sales, LLC v. Sandoz, Inc., 15-0347 (E.D. Tex.) | Mar. 9, 2015 | Hon. Rodney Gilstrap |
Combigan® (brimonidine tartrate /
timolol maleate ophthalmic solution)
|
7,030,149
7,320,976
7,642,258
8,748,425
|
| Ferrum Ferro Capital, LLC v. Allergan Sales, LLC, IPR2015-00858 (PTAB) | Mar. 9, 2015 | N/A |
Combigan®
(brimonidine tartrate /
timolol maleate ophthalmic solution)
|
7,030,149 |
| Sanofi-Aventis U.S. LLC v. Apotex Corp., 15-1835 (D.N.J.) | Mar. 11, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 8,927,592 |
| Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 15-1836 (D.N.J.) | Mar. 11, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 8,927,592 |
| Galderma Labs., L.P. v. Actavis Labs. UT, Inc., 15-0232 (D. Del.) | Mar. 12, 2015 | Hon. Leonard P. Stark | Mirvaso® (brimonidine topical gel) |
7,439,241
8,410,102
8,426,410
8,859,551
8,513,247
8,513,249
|
| Accord Healthcare Inc. v. Daiichi Sankyo Co., Ltd., IPR2015-00864 (PTAB) | Mar. 12, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,404,703 |
| Accord Healthcare Inc. v. Daiichi Sankyo Co., Ltd., IPR2015-00865 (PTAB) | Mar. 13, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,569,325 |
| Apotex Inc. v. Wyeth LLC, IPR2015-00873 (PTAB) | Mar. 12, 2015 | N/A | Tygacil® (tigecycline injectable IV infusion) | 7,879,828 |
| Horizon Pharma Ireland Ltd. v. Taro Pharms. USA, Inc., 15-2046 (D.N.J.) | Mar. 13, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00884 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,291,904 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00888 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,776,794 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00889 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,573,209 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00891 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,573,210 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00893 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,776,795 |
| Bristol-Myers Squibb Co. v. Mylan Pharms., Inc., 15-1949 (D.N.J.) | Mar. 17, 2015 | Hon. Freda L. Wolfson | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Otsuka Pharm. Co., Ltd. v. Indoco Remedies Ltd., 15-1967 (D.N.J.) | Mar. 17, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Bristol-Myers Squibb Co. v. Mylan Pharms., Inc., 15-0049 (N.D.W.V.) | Mar. 19, 2015 | Hon. Irene M. Keeley | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-00902 (PTAB) | Mar. 19, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,669,290 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-00903 (PTAB) | Mar. 19, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,129,431 |
| Noven Pharms., Inc. v. Actavis Labs. UT, Inc., 15-0249 (D. Del.) | Mar. 20, 2015 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 8,231,906 |
| Merck Sharp & Dohme Corp. v. Amneal Pharms. LLC, 15-0250 (D. Del.) | Mar. 20, 2015 | Hon. Sue L. Robinson | Nasonex® (mometasone furoate monohydrate metered nasal spray) | 6,127,353 |
|
Boehringer Ingelheim Pharma GmbH & Co. KG v.
Breckenridge Pharm., Inc., 15-80377 (S.D. Fla.)
|
Mar. 20, 2015 | Hon. Kenneth A. Marra | Pradaxa® (dabigatran etexilate mesylate capsules)) | 6,087,380 |
| Helsinn Healthcare S.A. v. Hospira, Inc., 15-2077 (D.N.J.) | Mar. 23, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Helsinn Healthcare S.A. v. Par Pharm. Cos., Inc., 15-2078 (D.N.J.) | Mar. 23, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-0260 (D. Del.) | Mar. 24, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,652,497
|
| Helsinn Healthcare S.A. v. Hospira, Inc., 15-0264 (D. Del.) | Mar. 25, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Helsinn Healthcare S.A. v. Par Pharm. Cos., Inc., 15-0265 (D. Del.) | Mar. 25, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-11294 (D. Mass.) | Mar. 26, 2015 | Hon. F. Dennis Saylor, IV | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,652,497
|
| Reckitt Benckiser LLC v. Amneal Pharms LLC, 15-2155 (D.N.J.) | Mar. 26, 2015 | Hon. Claire C. Cecchi | Mucinex® (guaifenesin extended-release tablets) |
6,372,252
6,955,821
7,838,032
|
| Reckitt Benckiser LLC v. Perrigo Co., 15-2156 (D.N.J.) | Mar. 26, 2015 | Hon. Claire C. Cecchi | Mucinex® (guaifenesin extended-release tablets) |
6,372,252
6,955,821
7,838,032
|
| Novo Nordisk Inc. v. Baxter Healthcare Corp., 15-2157 (D.N.J.) | Mar. 26, 2015 | Hon. Peter G. Sheridan | Novoeight® (turoctocog alfa) |
6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
|
| Forest Labs., LLC v. Accord Healthcare Inc., 15-0272 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Forest Labs., LLC v. Alembic Pharms. Ltd., 15-0273 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Forest Labs., LLC v. Apotex Inc., 15-0274 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Forest Labs., LLC v. Teva Pharms. USA, Inc., 15-0275 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| McNeil-PPC, Inc. v. Watson Labs., Inc., 15-2197 (D.N.J.) | Mar. 27, 2015 | Hon. Madeline C. Arleo | Rogaine® (5% minoxidil topical aerosol foam) | 6,946,120 |
| Forest Labs., LLC v. Invagen Pharms. Inc., 15-0277 (D. Del.) | Mar. 30, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
